BioE 1115

Drug Profile

BioE 1115

Alternative Names: BioE-1115

Latest Information Update: 08 Jul 2016

Price : $50

At a glance

  • Originator BioEnergenix
  • Class Small molecules
  • Mechanism of Action PAS domain kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Dyslipidaemias; Metabolic syndrome

Most Recent Events

  • 08 Jul 2016 BioE 1115 is available for licensing as of 08 Jul 2016. http://www.bioenergenix.com
  • 04 Jul 2016 Preclinical trials in Dyslipidaemias in USA (PO)
  • 04 Jul 2016 Preclinical trials in Metabolic syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top